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Abbreviations 
 
PBG: Post prandial blood glucose level 
FBG: Fasting blood glucose level 
SU: Sulfonylureas 
POP: Proof of principle 
JP: Japanese pharmacopoeia 
JP1 fluid: Japanese pharmacopoeia 16, disintegration test fluid No.1 
JP2 fluid: Japanese pharmacopoeia 16, disintegration test fluid No.2 
Cmax: Maximum plasma concentration of administered drug 
Tmax: The time after administration when the maximum plasma concentration is 
reached 
PPARγ: Peroxisome proliferator-activated receptor γ 
GLP-1: Glucagon-like peptide-1 
DPP- IV: Dipeptidyl peptidase-4 
SGLT2: Sodium/glucose co-transporter 2 
α-GI: α-Glucosidase inhibitor 
HbA1c: Hemoglobin A1c 
JDS: The Japan diabetes society 
NGSP: National glycohemoglobin standardization program 
NG: No good 
DDS: Drug delivery system 
HPMCP: Hydroxypropylmethylcellulose phthalate 
HPC: Hydroxypropylcellulose 
vi 
HPMC: Hydroxypropylmethylcellulose 
Mg-St: Magnesium stearate 
QASD: Quick action/short duration 
NDA: New drug application 
N.S.: Not significant 
AUC: Area under the plasma concentration-time curve 
b.i.d. (bis in die): Administered twice a day  
SD: Standard deviation 
SEM: Standard Error 
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Chapter 1 
Background 
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Importance of Controlling Blood Glucose Level for Diabetes 
There are 2 kinds of diabetes1). The one is “Diabetes mellitus type 1”, the other is 
“Diabetes mellitus type 2”. Diabetes mellitus type 1 is a disease caused by the lack of 
insulin. Insulin must be administered for type 1 by injection or inhalation. Diabetes 
mellitus type 2 is due to lack of insulin release, insulin resistance by cells, and so on. 
Treatments for type 2 are,  
(1) using agents that increase the amount of insulin secreted by the pancreas  
(2) using agents that increase the sensitivity of target organs to insulin  
(3) using agents that decrease the rate at which glucose is absorbed from the 
gastrointestinal tract. 
Some drugs are used often in combination.  
Ordinary oral antidiabetics for type 2 are classified into two types1-19). The first type 
primarily controls PBG, while the other type primarily controls FBG2, 3). There is 
currently no oral antidiabetic capable of controlling both PBG and FBG, and such an 
antidiabetic is believed to be the most useful for the treatment of diabetes.  Table 1-1 
shows anti-diabetic oral preparations for type 2 diabetes on the market.  
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Table1-1: Typical anti-diabetic oral preparations for type 2 diabetes on the market4-19). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Increasing insulin secretion from the pancreas has been the major area targeted to 
treat type 2 diabetes. SU agents increase insulin secretion1). They primarily lower FBG 
by increasing the release of insulin from the pancreas. The first generations of these 
drugs include tolbutamide, while the2nd drugs include gliclazide (Glimicron®)4), 
Glibenclamide (Euglucon®)5), and the 3rd drugs include glimepiride (Amaryl®)6). 
Sulfonylureas have the risk of causing hypoglycemia.  
  
Drug substance Type Drug product Maker
Gliclazide Glimicron ®
Dainippon Sumitomo
Pharm.
Glibenclamide Euglucon® Chugai Pharmaceutical
Glimepiride Amaryl® Sanofi
Nateglinide Fastic®
Ajinomoto
Pharmaceutical
Repaglinide Surepost®
Dainippon Sumitomo
Pharm.
Mitiglinide Glufast® Kissei
Pioglitazone  thiazolidinediones Actos® Takeda Pharmaceutical
Metformin biguanides Metgluco®
Dainippon Sumitomo
Pharm.
Voglibose Basen® Takeda Pharmaceutical
Acarbose Glucobay® Bayer
Sitagliptin phosphate  DPP -IV inhibitors Januvia® MSD
Tofogliflozin Deberza® Kowa
Ipragliflozin Suglat® Astellas
Canagliflozin Canaglu® Tanabe-Mitsubishi
Empagliflozin Jardiance®
Boehringer Ingelheim,
Japan
Sergliflozin etabonate
 alpha glucosidase
inhibitors
SGLT-2 inhibitors
sulfonylureas
meglitinides
under developing
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Figure 1-1: Chemical structure of sulfonylureas. 
Representative examples were indicated. 
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Meglitinides help the pancreas insulin secretion and are often called "short-acting 
type insulin secretagogues”. Meglitinides primarily decrease PBG by increasing the 
release of insulin from the pancreas. Meglitinides include nateglinide7), repaglinide8) 
and mitiglinide9). These drugs have to be taken just before meal to show post prandial 
blood glucose levels lowering effect. In this study, nateglinide was used as an active 
ingredient for controlled release formulation design. 
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mitiglinide 
 
 
 
 
 
Figure 1-2: Chemical structure of meglitinides. 
Representative examples were indicated. 
 
 
Thiazolidinediones are known as "glitazones" which bind to PPARγ, a type of 
nuclear regulatory proteins involved in transcription of genes regulating glucose and 
fat metabolism. Thiazolidinediones primarily decrease FBG. They include 
pioglitazone10). 
 
pioglitazone 
             
 
 
 
 
 
Figure 1-3: Chemical structure of thiazolidinediones. 
          Representative examples were indicated. 
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Biguanides reduce hepatic glucose output and increase the uptake of glucose by the 
periphery, including skeletal muscle. They primarily decrease FBG, and include 
metformin11). Metformin has become the most commonly used agent for type 2 
diabetes.  
               metformin 
             
 
    
Figure 1-4: Chemical structure of biguanides. 
    Representative examples were indicated. 
 
 
 
Alpha-glucosidase inhibitors do not have a direct effect on insulin secretion or 
sensitivity. These agents slow the digestion of carbohydrates in the small intestine, so 
that glucose derived from the carbohydrates in a meal is absorbed more slowly. They 
primarily decrease PBG. They include voglibose12) and acarbose13). They have to be 
taken just before a meal to show PBG lowering effect. 
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Figure 1-5: Chemical structure of alpha glycosidase inhibitors. 
          Representative examples were indicated. 
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GLP-1 works on glucose-mediated insulin secretion. It is broken down by an 
enzyme called DPP- IV. So DPP-IV inhibitors promote insulin secretion. They include 
sitagliptin phosphate14). They fundamentally control both PBG and FBG, if the blood 
glucose level is high. However further clinical research is necessary. 
 
sitagliptin 
 
 
 
 
 
Figure 1-6: Chemical structure of DPP-IV inhibitors. 
    Representative examples were indicated. 
 
 
 
SGLT2 is a member of the sodium glucose cotransporter family which are 
sodium-dependent glucose transport proteins. SGLT2 is the major co-transporter 
involved in glucose the reabsorption in the kidney. When inhibiting SGLT2, the 
reabsorption of glucose in the kidney is restricted, consequently blood glucose level 
decreases. Some drugs have been in the market and others are currently undergoing 
clinical trials. 
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sergliflozin 18) 
 
 
 
 
 
  
canagliflozin19) 
 
 
 
 
     
Figure 1-7: Chemical structure of SGLT-2 inhibitors. 
             Representative examples were indicated. 
 
Rosiglitazone/metformin (Avandamet®)20), pioglitazone/glimepiride (Duetact®)21) 
and pioglitazone/metformin (Actosplusmet®)22) are new combination drug products 
that are on the market to treat diabetes. The benefit with these combination drugs is to 
lead to better compliance, because there are fewer tablets to take. However, the above 
drug products cannot effectively/timely control both PBG and FBG.  
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It is important to control the blood glucose level so as to prevent complications, such 
as microangiopathy, atherosclerosis. Evaluation items and control levels are shown in 
Table 1-2. HbA1c values are indexes that reflect average blood glucose levels of 
diabetes. It is the first selection index of diabetic control and patient's self-management. 
However, circadian variation of blood glucose levels is not able to be estimated by 
HbA1c values. Furthermore, there are other factors that change HbA1c values. Not 
only HbA1c values but FBG, PBG (after the meal in 2 hr), blood glucose level profile 
should be considered so as to estimate control level of diabetes1).  
 
Table 1-2: Evaluation item and control level1). 
 
 
 
 
 
 
 
 
NGSP value (%) = JDS (%) × 1.02 + 0.25 
  
 Control level
Evaluation item
6.5-7.9 (Insufficient)
7.0-8.0 (defect)
6.9-7.4 (Insufficient)
7.4-8.4 (defect)
FBG (mg/dL) 80-110 110-130 130-160 160 or more
PBG (mg/dL)
(after the meal in 2 hr)
Excellent Good Fair Poor
80-140 140-180 180-220 220 or more
HbA1c (%) (JDS) Less than 5.8 5.8-6.5 8.0 or more
HbA1c (%)
(International, NGSP) Less than 6.2 6.2-6.9 8.4 or more
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Generally, the treatment plan for type 2 diabetes as shown in the Figure 1-8 is 
conducted23). If it is impossible to decrease blood glucose levels by control of amount 
of meal/activity, oral preparation for diabetes is necessary. If it is impossible with the 
oral preparation, insulin therapy is necessary.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-8: Treatment of diabetes23). 
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DDS Technology for Oral Administration 
When considering oral DDS technology, it is important to understand 
gastro-intestinal transit time and pH in human (Figure 1-10). DDS technologies as 
below are known24), and show in each of the following paragraphs in detail.  
 
     ○ pH Dependent technology 
        Material that is dissolved by triggering pH is used.  
        Dosage form: Enteric coated tablets, Enteric coated granules,  
 Enteric matrix tablets, Enteric matrix granules 
     ○ Time dependent technology 
        Material that is dissolved slowly, or not dissolved is used. 
        Dosage form: Coated tablets, Coated granules,  
 Matrix tablets, Matrix granules 
     ○ Others  
     Material that is dissolved/decomposed by flora in the gut is used. 
        Dosage form: Tablets, Granules 
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          Table1-3: Typical enteric coating materials. 
 
 
 
 
 
 
<Enteric coated granules> 
Enteric coated granules are obtained by the coating with enteric coating material on 
core granules. Core granules refer to the original granules to be coated. Core granules 
can be manufactured by obtaining granules that contain the drug and have a shape 
suitable for coating, for example using an extrusion granulation method and high speed 
stirring granulation method. With highly plasticized coating film, the obtained enteric 
coated granules are able to be compressed to prepare tablet formulation26). 
<Enteric coated tablets> 
Enteric coated tablets are obtained by coating with an enteric coating material on 
core tablets. Core tablets refer to the original tablets to be coated. Core tablets can be 
manufactured with a tableting machine. Coating methods include a fluidized bed 
coating method and a tumbling coating method for granules. On the other hand, the 
methods include a pan coating method for tablets.  
<Enteric matrix (granules, tablets)> 
An enteric matrix is obtained by mixing enteric material and active ingredient, and 
the mixture is compressed. The form includes a granule or a tablet. Details are 
Generic Name Trade Name / Grade Maker
dry methacrylic acid copolymer LD /
 methacrylic acid copolymer LD
Eudragit®L100-55 /
Eudragit®L30D-55
Röhm GmbH
methacrylic acid copolymer S Eudragit®S100 Röhm GmbH
methacrylic acid copolymer L Eudragit®L100 Röhm GmbH
hydroxypropylmethylcellulose phthalate HPMCP Shinetsu Chemical
hydroxypropylmethylcellulose acetate
succinate
AQOAT® Shinetsu Chemical
- 18 - 
described in <Enteric coated granules>, <Enteric coated tablets>.   
 
Regarding time dependent technology, poor-water soluble materials are generally 
used24,25). Coating or granulating or tableting is conducted with the materials. The 
materials are non-ionic polymers, such as poly acrylic polymer derivatives and poly 
saccharides derivatives. Typical materials are shown in Table 1-4. The obtained time 
dependent release formulation shows the time dependent release. The release behavior 
shows “prolonged”. About a formulation form, it is similar to the contents described in 
<Enteric coated granules>, <Enteric coated tablets>. 
 
   Table1-4: Typical time dependent release coating materials. 
 
 
 
Degradable/non degradable formulation is obtained by dispersing a drug in a “gel 
structure” comprising of poor-water soluble materials / water sellable materials / water 
soluble polymers24). They are classified into two types. One is a degradable (erosion) 
type, and another is a non-degradable (non-erosion) type. Typical matix materials are 
shown in Table 1-5. The erosion type matrix formulation is obtained with water soluble 
polymers. On the other hand, non-degradable matrix formulation is obtained with 
poor-water soluble materials. The obtained matrix formulation shows a pH dependent 
release, a time dependent release or a timed release profiles in vitro. 
Matrix granules can be manufactured by obtaining granules that contain the drug, 
for example using an extrusion granulation method and a high speed stirring 
Generic Name Trade Name / Grade Maker
aminoalkyl methacrylate copolymer RS Eudragit®RSPO Röhm GmbH
ethylcellulose EC Dow chemical
- 19 - 
granulation method. Matrix tablets can be manufactured with a tableting machine. 
 
           Table 1-5: Typical matrix materials. 
 
 
 
 
 
 
 
Next, a modified release formulation containing both immediate release portion and 
controlled release portion is described24-27). Regarding the modified release formulation 
containing both immediate release granules and enteric coated granules, the modified 
release granules are obtained by mixing both immediate release granules and enteric 
coated granules27). Capsules are also obtained by filling the above mentioned granules 
into a capsule shell. With enteric coated granules comprising of highly plasticized 
enteric coating film26), a modified release tablet is able to be obtained. Figure 1-11 
shows the modified release tablet containing both immediate release granules and 
compressionable enteric coated granules. This formulation shows both an immediate 
release profile and a pH dependent release profile in vitro. This is obtained by tableting 
after mixing both immediate release granules and enteric coated granules with 
lubricants. As the enteric coating film is highly plasticized, acid resistance of enteric 
coated granules was maintained even after tableting.  
      
Generic Name Trade Name / Grade Maker
hydroxypropylcellulose HPC Nisso
hydroxypropylmethylcellulose HPMC Shinetsu Chemical
dry methacrylic acid copolymer LD /
 methacrylic acid copolymer LD
Eudragit®L100-55 /
Eudragit®L30D-55
Röhm GmbH
methacrylic acid copolymer S Eudragit®S100 Röhm GmbH
methacrylic acid copolymer L Eudragit®L100 Röhm GmbH
hydroxypropylmethylcellulose phthalate HPMCP Shinetsu Chemical
hydroxypropylmethylcellulose acetate
succinate
AQOAT® Shinetsu Chemical
aminoalkyl methacrylate copolymer RS Eudragit®RSPO Röhm GmbH
ethylcellulose EC Dow chemical
hydrogenated oil Caster wax NOF
degradable
non
degradable
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time dependent release profile in vitro.  
 
 
 
 
 
 
 
 
Figure 1-12: The section of controlled release tablet containing both a matrix tablet and 
immediate release granules. 
            Immediate release granules form an outer shell. 
 
The modified release formulation containing both an immediate release portion and 
a controlled release portion using nateglinide is expected to control both PBG and FBG 
(Figure 1-13).  
  
core tablet :  matrix tablet
outer shell
  
 
 
 
 
 
 
 
 
 
    
 
 
F
     
         
igure 1-13
         
         
: Pattern di
  Immedi
  Controll
 
- 22 - 
agram of bl
ate release p
ed release p
ood glucos
ortion dec
ortion dec
e levels. 
reases PBG
reases FBG
. 
. 
- 23 - 
Concern in Multiple Administration of Insulin Secretagogue 
It is thought that control of a blood glucose level might be possible with the 
controlled release formulation containing an insulin secretagogue, nateglinide, that 
demonstrates a quick action/short duration type effect3). If the nateglinide oral 
controlled release formulations were available that were capable of controlling both 
PBG and FBG, it could be expected to offer the advantages of (1) improving 
compliance by reducing the number of administrations per day (Fastic tablets: 3 
times per day; nateglinide immediate release tablet), and (2) increasing the number of 
choices available for treating diabetes in moderate and severe diabetes patients.   
Nateglinide stimulates insulin secretion. It has a different chemical structure from 
sulfonylureas3), and its effect is believed to effectively control primarily PBG. Since 
blood glucose level inhibitory effects dissipate in a short period of time, nateglinide is 
expected to realize (1) avoidance of a hypoglycemic state, and (2) avoidance of  cell 
exhaustion following long-term administration and avoidance of secondary failure 3).  
Gliclazide is an anti-diabetic agent that is a long acting type stimulator of insulin 
secretion having a sulfonylurea moiety. In the case of repeated administration of 
gliclazide to normal rats, the blood glucose lowering effect has been reported to 
weaken during the second administration3) (Figure 1-14). Consequently, in the case of 
designing a controlled release formulation that contains nateglinide for the purpose of 
effectively inhibiting both PBG and FBG, there have been concerns that even if it is 
possible to control PBG, it may not be possible to adequately control FBG.  
On the other hand, both nateglinide and SU agents bind on the SU receptor. 
However, it was reported that nateglinide dissociates rapidly more than SU dose29). 
Then the author expected that it is possible to decrease both PBG and FBG with 
mult
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Chapter 2  
Effect of Decrease in both PBG and FBG in Normal Beagle 
Dogs with Controlled Release Form of Nateglinide 
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2.1.  Design of Nateglinide Enteric Coated Granules and Evaluation 
of Dissolution Profile 
 
Summary 
The D-phenylalanine derivative, nateglinide ((-)-N-(trans-4-isopropylcyclo- 
hexanecarbonyl)-D-phenylalanine, Figure 1-2) is a new QASD type of oral blood 
glucose regulator. In this chapter 2, the author attempted to determine if it was possible 
to control both PBG and FBG in normal beagle dogs with controlled release of 
nateglinide. Enteric coated granules were selected for the administration form for 
controlled release of nateglinide, and three types of enteric coated granules were 
prepared by fluidized bed coating. The obtained granules had good acid resistance and 
dissolution pH values of 5.5, 6.5 and 7.2 respectively.   
 
Material and Methods 
Nateglinide (Ajinomoto Co. Inc., Japan),  lactose mono-hydrate (DMV Japan), 
hydroxypropylcellulose, low-substituted hydroxypropylcellulose (Shin-etsu Chemical 
Co. Ltd., Japan), dry methacrylic acid copolymer LD (Röhm GmbH, Germany), 
methacrylic acid copolymer S (Röhm GmbH, Germany), 
Hydroxypropylmethylcellulosephtalate220824 (HPMCP HP-50, Shinetsu Chemical Co. 
Ltd., Japan), macrogol6000 (Nihon Oil and Fats Co. Ltd., Japan), talc and ethanol 
(Wako pure chemical, Japan) were used in the study. Fastic  tablets  (Ajinomoto Co. 
Inc., Japan) were used as an immediate release tablets.  
An extrusion granulator (DG-L1, Fuji Paudal, Japan), spherized granulator (Q-230, 
Fuji Paudal, Japan), fluidized bed granulator (FLO-1, Freund industry Co., Japan)  
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and homogenizer (T25-ST, JANEE & KUNKEL GMBH Co. KG, Germany) were 
used. 
Two hundred and fifty grams of nateglinide, 10 g of hydroxypropylcellulose, and 
425 g of lactose mono hydrate were suspended and dissolved in 815 g of water with a 
homogenizer. After mixing this suspension with 300 g of low-substituted 
hydroxypropylcellulose, extrusion granulation was conducted. The resulting granules 
were rounded by a spherical granulator, and then dried in a fluidized bed dryer. 
Fractions of 500 μm - 1400 μm granules were obtained by grading, and then used for 
coating. 
Table 2-1 shows the compositions of the enteric coating solutions. The resulting core 
granules were coated with the coating solutions using a fluidized bed coating machine 
(FLO-1, Freund Ind., Japan). Three types of enteric coated granules were obtained 
consisting of enteric coated granules A  
(hydroxypropylmethylcellulosephtalate220824), enteric coated granules B (dry 
methacrylic acid copolymer LD), enteric coated granules C (methacrylic acid 
copolymer S).  
 
Table 2-1: Composition of each enteric-coating solution [w/w%]. 
 
 
 
 
 
 
A B C
Eudragit L100-55 - 7.0 -
Eudragit S100 - - 7.0
HPMCP HP-50 7.0 - -
macrogol6000 0.7 0.7 0.7
talc 1.0 3.5 3.5
ethanol 73.0 70.0 70.0
water 18.3 18.8 18.8
enteric coated granules
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The dissolution profiles of the resulting granules were evaluated (JP16, paddle 
method, 50 rpm, test fluid: 900 mL, nateglinide: 90 mg/vessel) with a dissolution tester
（NTR-VS6P, Toyama sangyo Co. Ltd., Japan）. The test fluids consisted of JP1 fluid  
containing 0.6 w/v% polysorbate 80 for pH=1.2, four-time diluted McIlvaine buffer 
(pH=4.0) containing 0.5 w/v% polysorbate 80 for pH=4.0, and Clark-Lubs buffer for 
pH=5.5-7.6.  
Dissolution rates were determined with a reversed phase HPLC system consisting of 
an L-6000 constant flow pump and a L-4000 UV detecter operating at 210 nm (Hitachi 
Corp., Japan). Separations were performed with a reversed phase C-18 column 
(4.5×150 mm, GL Science, Japan). The mobile phase consisted of acetonitrile – 
pH=2.5 phosphate buffer  (55:45, v/v).  Nateglinide eluted at about 10 min at 40oC 
(at a flow rate of 1.5 mL/min). 
 
Results 
Nateglinide core granules were coated using the coating solutions shown in Table 
2-1 to prepare three types of nateglinide enteric coated granules. An evaluation was 
first made of the relationship between the coated amount of enteric coating material 
(dry methacrylic acid copolymer LD, Eudragit® L100-55) and acid resistance (value 
of dissolution rate at 120 minutes in JP1 fluid containing 0.6 w/v% Polysorbate 80) 
through coating using methacrylic acid copolymer LD coating solution (Figure 2-1). 
The 120 minute dissolution rate at pH 1.2 decreased as the coated amount increased, 
and acid resistance was obtained when coated to about 15 w/w% or more. Namely, the 
120 minute dissolution rate at pH 1.2 was found to be 10% or less. Enteric coated 
granules B were obtained by coating with dry methacrylic acid copolymer LD at 32.5 
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w/w%. With reference to the results described above, enteric coated granules A 
and  C  were  obtained  by  coating  the  same  core  granules  with 
hydroxyproprylmethylcellulose phthalate 220824 and methacrylic copolymer S at 24.0 
w/w% and 33.9 w/w%, respectively. As shown in Table 2-2, the 120 minute dissolution 
rates at pH 1.2 of enteric coated granules A, B and C were all 10% or less and 
confirmed to demonstrate sufficient acid resistance.   
Moreover, dissolution behavior in the neutral pH region was also evaluated for the 
resulting enteric coated granules (Figure 2-2).  Here, the dissolution behavior of each 
the enteric coated granules was classified based on the approach of dissolution pH27). 
In this study, dissolution pH is defined as the pH at which the 60 minute dissolution 
rate reaches 10% or more.  Enteric coated granules A, B and C were confirmed to 
each have different dissolution pH, demonstrating values of 5.5, 6.5 and 7.2, 
respectively. 
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Figure 2-1: Relationship between an amount of enteric coating material and enteric 
property. 
Dry methacrylyc acid copolymer LD was used as an enteric coating 
material.  
JPXIII paddle method (50 rpm), n=3, nateglinide: 90 mg/vessel,  
          Medium: JP1 fluid containing 0.6 w/w% polysorbate 80. 
 
Table 2-2: Enteric property of the obtained granules. 
         *: JP1 fluid containing 0.6 w/w% polysorbate 80, mean ± SD (n=3).    
 
 
 
enteric coated granules %dissolved in JP1fluid
* at
120min [%]
A 0.9±0.3
B 1.4±0.3
C 0.5±0.0
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Figure 2-2: pH Dissolution relationship for 3 types of enteric coated granules.   
JPXIII paddle method (50 rpm), n=3, nateglinide: 90 mg/vessel,  
mean ± SD, medium: pH=4.0: McIlvaine buffer 4 times diluted with 
water (0.5 w/v% polysorbate 80), pH=5.5〜7.6: Clark-Lubs buffer 
(KH2PO4 + NaOH). 
○: enteric coated granules A, ᇞ: B, □: C. 
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Discussion 
Nateglinide is poorly water soluble drug. Polysorbate 80 was added to acid pH 
testing fluid to satisfy sink condition. Figure 2-1 indicates that the surfaces of the core 
granules are covered with an enteric coating having adequate acid resistance as a result 
of coating the enteric coating material at 15 w/w%.  
Dissolution behavior in the neutral pH region was also evaluated for the resulting 
enteric coated granules. Here, the dissolution behavior of each the enteric coated 
granules was classified based on the approach of dissolution pH as advocated in 
reference 27. In this study, dissolution pH is defined as the pH at which the 60 minute 
dissolution rate reaches 10% or more. Enteric coated granules A, B and C were 
confirmed to each have different dissolution pH, demonstrating values of 5.5, 6.5 and 
7.2, respectively. The enteric coating materials used for enteric coated granules A, B 
and C have been reported to dissolve at pH 5.0, 6.0 and 7.0, respectively30). The trends 
of the dissolution pH values of the resulting enteric coated granules agreed with the 
trends of the pH values at which the enteric coating materials dissolve. Furthermore, 
the dissolution rate of nateglinide immediate release tablets (Fastic® tablets) under the 
same conditions is nearly 100%. On the basis of the above results, enteric coated 
granules A, B and C were confirmed to elute more slowly than nateglinide immediate 
release tablets, and the their degrees of controlled release were each found to be 
different, with their dissolution rates becoming slower in the order of enteric coated 
granules A, B and finally C. When these enteric coated granules are administered with 
food, controlled release of nateglinide is expected.   
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2.2. Nateglinide Plasma Concentration Profile, Insulin Plasma 
Concentration Profile and Blood Glucose Level When 
Administering Nateglinide Enteric Coated Granules just before 
Feeding in Normal Beagle Dogs 
 
Summary 
The obtained three types of enteric coated granules were each administered 
separately to normal beagle dogs just before feeding followed by measurement of 
plasma nateglinide concentration, plasma insulin concentration and blood glucose level. 
In the case of administering enteric coated granules alone (nateglinide: 9 mg/kg), the 
absorption of nateglinide was confirmed to tend to be delayed as the dissolution pH 
increased.  In the case of an dissolution pH of 5.5, decreases in both PBG and FBG 
were observed.  In the case of dissolution pH values of 6.5 and 7.2, only decrease in 
FBG was observed. In case of nateglinide immediate release tablets (nateglinide: 9 
mg/kg), only decrease in PBG was observed. 
    
Materials and Methods 
The three types of enteric coated granules were obtained in 2.1. Fastic  tablets  
(nateglinide: 30mg/tablet, Ajinomoto Co. Inc., Japan) were used as an immediate 
release tablets in vivo study. Prior to being conducted, in vivo studies were assessed 
according to the guidelines of Ethical Committee in INA Research Co., Ltd. (Japan). 
The guideline was established based on "Doubutsu no aigo oyobi kanri ni kannsuru 
houritsu (Law about protection of an animal and management)" (October 1st, 1973, No. 
105), "Jikkendoubutsu no shiyou oyobi hokan nado ni kansuru kijyun (The standard 
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about the breeding of an experimental animal and the safekeeping, etc.)" (March 1st, 
Sourihu No. 6), “Jikkendoubutsu gaidorain no sakutei ni tsuite (About decision of an 
animal experiment guideline)" (November 5th, 1980, Sougakusho No. 1513), "Daigaku 
nado ni okeru doubutsujikken ni tsuite (About the animal experiment that is conducted 
in a university" (May 25th, 1987, Bungakujyou No. 141). Nateglinide preparations 
were administered to normal male beagle dogs (body weight: ca. 10 kg) just before 
feeding. One hundred and fifty grams of dry DS meal suspended in 600 g of hot water 
was forcibly administered to the beagle dogs with a syringe. Feeding was conducted 
within 12 min. In case of oral administration of enteric coated granules (nateglinide: 9 
mg/kg),  only feeding, immediate release tablets (nateglinide: ca. 9 mg/kg), blood 
samples were taken before and at 15, 30, 45, 60, 120, 180, 240, 360, 480 min (enteric 
coated granules: n=3, only feeding: n=6). Blood was sampled from a leg vein. Whole 
blood was centrifuged at 1700 g for 15 min at 5oC and plasma was collected for 
analysis. A 50 μL aliquot of internal standard solution was spiked into 0.5 mL plasma 
in an Eppendorf tube followed by the addition of 0.5 mL of 0.05 mol/L pH=6.0 
phosphate buffer. The mixture was vortex-mixed for 10 s and applied to a Sep-Pak Vac 
tC18 cartridge which was pre-equilibrated with 5 mL of 0.05 mol/L pH=6.0 phosphate 
buffer. The cartridge was washed with 2 mL of water and finally eluted with 2 mL of 
ethanol. The elute was evaporated to dryness in vacuo at 30oC. The residue was 
dissolved in 0.2 mL of mobile phase and 20 μL of this solution was used for the HPLC 
sample. Plasma nateglinide concentration was determined with a two-column 
switching HPLC system consisting of a 600E multi solvent pump system, 515 HPLC 
pump (Waters, Japan), 2487 UV detector (Waters, Japan) operating at 210 nm, and  
SPV-N-6A column switching apparatus (GL Science, Japan). Separations were 
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performed with an Inertsil ODS-3 reversed phase C-18 column (4.0×20 mm, GL 
Science, Japan) and L-column ODS (4.6×250 mm, Kagakubushitsukenkyukikou, 
Japan)31). Three types of mobile phases were used consisting of acetonitrile : pH=6.6 
0.05 mol/L phosphate buffer = 3:7 v/v (mobile phase A), acetonitrile: pH=6.6 0.05 
mol/L phosphate buffer = 45:55 v/v (mobile phase B), and acetonitrile : pH=6.6 0.05 
mol/L phosphate buffer = 6:4 v/v (mobile phase C). The time table of the column 
switching pattern is shown in Table 2-3. At a flow rate of 1.0 mL/min, nateglinide 
eluted at about 7.5 min at 40oC31). 
 
Table 2- 3 : Column switching program31). 
 
 
 
 
 
 
 
 
Determination of plasma insulin concentration was conducted using a kit for assay 
of insulin in plasma （Morinaga Seikagakukenkyusho Co. Ltd., Japan）. Blood glucose 
level was determined with the Fuji DRICHEM 3500S (FUJIFILM Co., 
Japan).Statistical analyses were performed by using the Student’s t-test. 
  
time[min.] 600E pump system 515 pump column switchinga)
0.0-0.7 Mobile Phase A Mobile Phase B 1
0.7-2.5 Mobile Phase A stop 2
2.5-8.0 Mobile Phase C Mobile Phase B 1
8.0-20.0 Mobile Phase A Mobile Phase B 1
a) 1: Mobile Phase A and C passed through a 600E pump system, injector and pre column.
       Mobile Phase B passed through a 515 pump, main column and detector.
    2: Mobile Phase A passed through a 600E pump system, injector, pre column, main column and detector.
       A 515 pump stopped.
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Results 
Enteric coated granules A, B and C were orally administered (nateglinide: 9 mg/kg) 
to normal beagle dogs just before feeding followed by measurement of plasma 
nateglinide concentrations, plasma insulin concentrations and blood glucose levels. 
Results are also shown for a control (feeding only) and immediate release tablets 
(nateglinide: 90 mg/body, ca. 9 mg/kg) used as controls. 
Plasma nateglinide concentration profiles are shown in Figure 2-3 (a).  The release 
of nateglinide is inhibited as the dissolution pH increases, eventually leading to 
delayed absorption. The Cmax values and AUC values of the enteric coated granules 
were lower than those of the immediate release tablets. However, an increasing trend 
was observed in plasma nateglinide concentrations of enteric coated granules B 
starting at 5 hr after administration as compared with that of the immediate release 
tablets.    
Plasma insulin concentration profiles are shown in Figure 2-3 (b).  The respective 
insulin Cmax values consisted of 1521385 pg/mL (Tmax: 2 hr) for the control (feeding 
only), 3349488 pg/mL (Tmax: 0.75 hr) for the immediate release tablets , 29471169 
pg/mL (Tmax: 0.75 hr) for enteric coated granules A, 2163337 pg/mL (Tmax: 1 hr) for 
enteric coated granules B, and 1985524 pg/mL (Tmax: 1 hr) for enteric coated granules 
C.  There were significant differences observed (p<0.05, Student's t-test) for plasma 
insulin concentrations from 0.25 hr to 1hr between the immediate release tablets and 
the control. And there were no significant differences observed for plasma insulin 
concentrations starting at 3 hr after administration between the enteric coated granules 
dose groups or between the enteric coated granules dose groups and the control 
(Student's t-test).  In addition, there was no correlation observed between plasma 
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nateglinide concentration and plasma insulin concentration .   
Blood glucose level profiles are shown in Figure 2-3 (c).  In the case of enteric 
coated granules B (dissolution pH: 6.5) and enteric coated granules C (dissolution pH: 
7.2), FBG decreased to a maximum of about 83% and about 86%, respectively, as 
compared with blood glucose levels immediately before administration.  In the case 
of enteric coated granules A (dissolution pH: 5.5), both FBG and PBG decreased, with 
both decreasing to a maximum of about 82% as compared with blood glucose levels 
immediately before administration. In case of the immediate release tablets, FBG at 8 
hr after administration did not decrease, although PBG decreased to a maximum of 
about 79% as compared with blood glucose levels immediately before administration. 
  
- 38 - 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
(continued) 
0
5
10
15
20
25
0 2 4 6 8
Pl
as
m
a 
na
te
gl
in
id
e 
[μg
/m
L]
Time [hr]
(a)
0
1000
2000
3000
4000
5000
0 2 4 6 8
Pl
as
m
a 
in
su
lin
  
[p
g/
m
L]
Time [hr]
(b)
- 39 - 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3: Plasma nateglinide concentration profile (a), plasma insulin 
concentration profile (b), blood glucose level (%initial) (c), after oral 
administration of enteric coated granules A (○), B △( ), C (□) 
(nateglinide: 9 mg/kg) and immediate release tablets (×) (nateglinide: 
ca.9 mg/kg) in beagle dogs just before feeding, or only feeding (-).  
Each point and vertical bar represent mean ± SEM (enteric coated 
granules: n=3, immediate release tablets and only feeding: n=6). 
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Discussion 
The obtained three types of enteric coated granules were each administered 
separately to normal beagle dogs just before feeding followed by measurement of 
plasma nateglinide concentration, plasma insulin concentration and blood glucose level. 
In the case of administering enteric coated granules alone (nateglinide: 9mg/kg), the 
absorption of nateglinide was confirmed to tend to be delayed as the dissolution pH 
increased. This means nateglinide dissolved from enteric coated granules slowly in 
vivo.  
There was no correlation observed between plasma nateglinide concentration and 
plasma insulin concentration. It is not obvious why there was no correlation although 
nateglinide was an insulin secretagogue. Further study is required.  
 In the case of an dissolution pH of 5.5, decreases in both PBG and FBG were 
observed.  In the case of dissolution pH values of 6.5 and 7.2, only decrease in FBG 
was observed. In case of nateglinide immediate release tablets (nateglinide : 9mg/kg), 
only decrease in PBG was observed. Although there appears to be a correlation 
between blood glucose level and plasma nateglinide concentration, there were no 
correlation between plasma insulin concentration and blood glucose level.  
On the basis of the above results, it was suggested that enteric coated granules have 
the ability of decrease in FBG, although immediate release tablets do not, and that only 
FBG or both PBG and FBG can be decreased by controlled release of a quick 
action/short duration type of blood glucose regulator, nateglinide.   
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2.3. Nateglinide Plasma Concentration Profile, Insulin Plasma 
Concentration Profile and Blood Glucose Level When 
Administering both Nateglinide Immediate Release Tablets and 
Enteric Coated Granules just before Feeding in Normal Beagle 
Dogs 
 
Summary 
The obtained enteric coated granules having an dissolution pH of 6.5 were 
administered simultaneous to administration of nateglinide immediate release tablets to 
normal beagle dogs just before feeding followed by measurement of plasma 
nateglinide concentration, plasma insulin concentration and blood glucose level. 
Decreases in both PBG and FBG were observed in the case of simultaneous 
administration of dissolution pH 6.5 enteric coated granules and nateglinide immediate 
release tablets just before feeding (nateglinide: 90 mg/head + 60 mg/head). A 
correlation was observed between plasma nateglinide concentrations and blood glucose 
levels.  On the other hand, there were no correlations observed between changes in 
plasma insulin concentrations and blood glucose levels. In case of nateglinide 
immediate release tablets (nateglinide: 150 mg/head), Decreases in both PBG and FBG 
were observed. However, the nateglinide controlled release formulation is more useful 
than the nateglinide immediate release tablets from the view point of avoidance of side 
effect, or of easy control of both PBG and FBG. In case of nateglinide immediate 
release tablets (nateglinide : 9 mg/kg), only decrease in PBG was observed. 
On the basis of these results, it is confirmed to decrease both PBG and FBG in 
normal beagle dogs with controlled release of nateglinide. Nateglinide controlled 
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release formulation is considered to enable control of both PBG and FBG for moderate 
and severe diabetes patients.     
 
Materials and Methods 
Enteric coated granules B were obtained in 2.1. Fastic  tablets  (nateglinide: 
30mg/tablet, Ajinomoto Co. Inc., Japan) were used as immediate release tablets in vivo 
study. 
Prior to being conducted, protocols of in vivo studies were assessed according to the 
guidelines of Ethical Committee in INA Research Co., Ltd. (Japan). The guideline was 
established based on "Doubutsu no aigo oyobi kanri ni kannsuru houritsu (Law about 
protection of an animal and management)" (October 1st, 1973, No. 105), 
"Jikkendoubutsu no shiyou oyobi hokan nado ni kansuru kijyun (The standard about 
the breeding of an experimental animal and the safekeeping, etc.)" (March 1st, Sourihu 
No.6), “Jikkendoubutsu gaidorain no sakutei ni tsuite (About decision of an animal 
experiment guideline)" (November 5th, 1980, Sougakusho No.1513), "Daigaku nado ni 
okeru doubutsujikken ni tsuite (About the animal experiment that is conducted in a 
university" (May 25th, 1987, Bungakujyou No.141). Nateglinide preparations were 
administered to normal male beagle dogs (body weight: ca. 10 kg) just before feeding. 
One hundred and fifty grams of dry DS meal suspended in 600 g of hot water was 
forcibly administered to the beagle dogs with a syringe. Feeding was conducted within 
12 min. In case of oral administration of both immediate release tablets and enteric 
coated granules B, blood samples were taken before and at 15, 30, 45, 60, 120, 240, 
360, 540, 720, 1440 min after oral administration for immediate release tablets only 
(nateglinide: 60, 150 mg), immediate release tablets (nateglinide: 60 mg) + enteric 
- 43 - 
coated granules B (nateglinide: 30 mg or 60 mg). Each point and vertical bar represent 
mean ± SEM (n=6). In case of oral administration of both immediate release tablets 
(nateglinide: 60 mg) + enteric coated granules B (nateglinide: 90 mg), blood samples 
were taken before and at 15, 30, 45, 60, 120, 180, 240, 360, 480, 540, 720, 1440 min 
after oral administration. Each point and vertical bar represent mean ± SEM (n=6), 
except at 180, 480, 540, 720, 1440 min (n=3). Blood sampling, determination of 
plasma nateglinide concentration, determination of plasma insulin concentration and 
statistical analysis were conducted according to 2.2. 
 
Results 
After deciding to focus on enteric coated granules B having a dissolution pH of 6.5 
which effectively lowered FBG with hardly any decrease in PBG, enteric coated 
granules B and nateglinide immediate release tablets (nateglinide: 60 mg) were 
simultaneously administered orally to normal beagle dogs just before feeding to 
evaluate the effects on PBG and FBG. Results are also shown for a control (feeding 
only) and nateglinide immediate release tablets only (nateglinide: 60 mg, 150 mg) used 
as controls.   
Plasma nateglinide concentration profiles are shown in Figure 2-4 (a).  The 
nateglinide Cmax values were 15.63  1.08 μg/mL (Tmax: 0.75 hr) , 34.80  5.15 μg/mL 
(Tmax: 0.5 hr) for the immediate release tablets (nateglinide: 60 mg, 150 mg), 12.59  
1.83 μg/mL (Tmax: 1 hr) for the immediate release tablets (nateglinide: 60 mg) + enteric 
coated granules B (nateglinide: 30 mg), 16.69  0.53 μg/mL (Tmax: 0.75 hr) for the 
immediate release tablets (nateglinide: 60 mg) + enteric coated granules B 
(nateglinide: 60 mg) and 15.60  2.08 μg/mL (Tmax: 1 hr) for the immediate release 
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tablets (nateglinide: 60 mg) + enteric coated granules B (nateglinide: 90 mg), 
respectively.  There were no significant differences of the Cmax values observed 
between the immediate release tablets (nateglinide: 60 mg) and the immediate release 
tablets (nateglinide: 60 mg) + enteric coated granules groups (Student's t-test). This is 
because Cmax values are only dependent on the immediate release component. On the 
other hand, plasma nateglinide concentrations from 3 hr to 12 hr after administration 
demonstrated an increasing trend accompanying an increasing amounts of nateglinide 
in the controlled release component (enteric coated granules B) . There were 
significant differences observed at  4, 6, 12 hr between the immediate release tablets 
(nateglinide: 60 mg) and the immediate release  tablets (nateglinide: 60 mg) + enteric 
coated granules B (nateglinide: 30 mg) , and at 2, 4, 6, 9, 12, 24 hr between the 
immediate release tablets (nateglinide: 60 mg) and the immediate release tablets 
(nateglinide: 60 mg) + enteric coated granules B (nateglinide: 60 mg), and at 2, 4, 6, 9, 
12, 24 hr between the immediate release tablets (nateglinide: 60 mg) and  the 
immediate release tablets (nateglinide: 60 mg) + enteric coated granules B 
(nateglinide: 90 mg). On the other hand, there were significant differences of plasma 
nateglinide concentration from 0.25 hr to 9 hr observed between the immediate release 
tablets (nateglinide: 60 mg) and the immediate release tablets (nateglinide: 150 mg) 
(p<0.05, Student's t-test).   
Plasma insulin concentration profiles are shown in Figure 2-4 (b).  The insulin Cmax 
values were 1521  385 pg/mL (Tmax: 2 hr) for the control, 3287  413 pg/mL (Tmax: 
0.75 hr), 4089  775 pg/mL (Tmax: 1 hr) for immediate release tablets (nateglinide: 60 
mg, 150 mg), 2758  599 pg/mL (Tmax: 0.75 hr) for immediate release tablets 
(nateglinide: 60 mg) + enteric coated granules B (nateglinide: 30 mg), 3600  446 
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pg/mL (Tmax: 0.75 hr) for immediate release tablets (nateglinide: 60 mg) + enteric 
coated granules B (nateglinide: 60 mg), and 3871  378 pg/mL (Tmax: 0.5 h) for 
immediate release tablets (nateglinide: 60 mg) + enteric coated granules B 
(nateglinide: 90 mg), respectively. There were significant differences of plasma insulin 
concentration observed  are  at 0.25, 0.5, 0.75 hr between the control (feeding only) 
and immediate release tablets (nateglinide: 60 mg), and at 0.25, 0.5, 1, 6 hr between 
the control (feeding only) immediate release tablets (nateglinide: 60 mg) + enteric 
coated granules B (nateglinide: 30 mg) , and at 0.25, 0.5, 1, 6 hr between the control 
(feeding only) and immediate release  tablets (nateglinide: 60 mg) + enteric coated 
granules B (nateglinide: 60 mg), and at 0.25, 0.5, 0.75, 1, 2, 4, 6 hr between the control 
( feeding only) and immediate release  tablets (nateglinide: 60 mg)+enteric coated 
granules B (nateglinide: 90 mg) (p<0.05, Student's t-test). On the other hand, in the 
case of comparing the groups administered enteric coated granules + immediate release 
tablets with the groups administered immediate release tablets (60 mg, 150 mg) only, 
there were no significant differences observed (Student's t-test) with the exception of 
the immediate release tablets (60 mg) + enteric coated granules (90 mg) at 24 hr after 
administration.  This significant difference observed at 24 hr after administration is 
thought to be an artifact.   
Blood glucose level profiles are shown in Figure 2-4 (c). In the case of comparing 
enteric coated granules + immediate relase tablets with nateglinide immediate release 
tablets (nateglinide: 60 mg), there were significant differences in blood glucose levels 
at 1, 2, 4, 6, 9 hr after administration in the immediate release tablets (nateglinide: 60 
mg) + enteric coated granules (nateglinide : 90 mg) group (p<0.05, Student's t-test).  
Based on the results of Figures 2-4 (a) and 2-4 (c), there is thought to be a 
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correlation between blood glucose levels and plasma nateglinide concentrations.  
Although decreases in blood glucose levels only continued for about 6 hr in the case of 
immediate release tablets (nateglinide: 60 mg), decreases continued for up to about 9 
hr in the case of simultaneous administration with enteric coated granules (immediate 
release tablets (nateglinide: 60 mg) + enteric coated granules (nateglinide: 90 mg) 
group).  
In case of immediate release tablets (nateglinide: 150 mg), the decrease in both PBG 
and FBG was observed. There were significant differences of blood glucose level 
observed at 6, 9, 12, 24 hr between the immediate release tablets (nateglinide: 150 mg) 
and the immediate release tablets (nateglinide: 60 mg) (p<0.05, Student's t-test).    
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Figure 2-4: Plasma nateglinide concentration profile (a), plasma insulin 
concentration profile (b), blood glucose level (c) after oral 
administration of both enteric coated granules B and immediate 
release tablets in fasted beagle dogs just before feeding, or only 
feeding.  
Each point and vertical bar represent mean ± SEM. 
－: only feeding. 
*: immediate release tablets (nateglinide: 60 mg). 
×: immediate release tablets(nateglinide: 150 mg). 
○: immediate release tablets (nateglinide: 60 mg) + enteric coated granules B 
(nateglinide: 30 mg). 
ᇞ: immediate release tablets (nateglinide: 60 mg) + enteric coated granules B 
(nateglinide: 60 mg). 
□: immediate release tablets (nateglinide: 60 mg) + enteric coated granules B 
(nateglinide: 90 mg). 
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Discussion 
The obtained enteric coated granules having an dissolution pH of 6.5 were 
administered simultaneous to administration of nateglinide immediate release tablets to 
normal beagle dogs just before feeding followed by measurement of plasma 
nateglinide concentration, plasma insulin concentration and blood glucose level.      
Decreases in both PBG and FBG were observed in the case of simultaneous 
administration of dissolution pH 6.5 enteric coated granules and nateglinide immediate 
release tablets just before feeding (nateglinide: 90 mg/head + 60 mg/head). A 
correlation was observed between plasma nateglinide concentrations and blood glucose 
levels.  On the other hand, there were no correlations observed between changes in 
plasma insulin concentrations and blood glucose levels. In case of nateglinide 
immediate release tablets (nateglinide: 150 mg/head), Decreases in both PBG and FBG 
were observed. However, the nateglinide controlled release formulation is more useful 
than the nateglinide immediate release tablets from the view point of avoidance of side 
effect, or of easy control of both PBG and FBG. In case of nateglinide immediate 
release tablets (nateglinide: 9 mg/kg), only decrease in PBG was observed. 
Not only the combination of the immediate release tablets (nateglinide: 60 mg) and 
enteric coated granules (nateglinide: 90 mg), but also the immediate release tablets 
(nateglinide: 150 mg) decreased both PBG and FBG. However, nateglinide controlled 
release formulation is believed to be more useful than the immediate release tablets 
(nateglinide: 150 mg) according to the reasons as follows. 
(1) The immediate release tablets (nateglinide: 150 mg) has higher Cmax of plasma 
nateglinide concentration than that of the combination of the immediate release 
tablets (nateglinide: 60 mg) and enteric coated granules (nateglinide: 90 mg). 
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The immediate release tablets (nateglinide: 150 mg) may have side effect 
(hypoglycemic state) easier than the combination of the immediate release 
tablets (nateglinide: 60 mg) and enteric coated granules (nateglinide: 90 mg). 
(2) It is easier to control both PBG and FBG with the combination of the immediate 
release tablets (nateglinide: 60 mg) and enteric coated granules (nateglinide: 90 
mg) than with the immediate release tablets (nateglinide: 150 mg), because the 
combination can adjust the balance of immediate release part and controlled 
release part. 
On the basis of these results, it was indicated that it is possible to lower both PBG and 
FBG by controlled release of nateglinide. It was also indicated that it is possible to 
control both PBG and FBG by using a combined immediate release and controlled 
release formulation containing nateglinide. 
 It was initially believed in this study that it would be difficult to lower fasting blood 
glucose levels even if the release of an insulin secretion stimulator like nateglinide was 
able to be controlled.  However, our study confirmed that it is possible to lower 
fasting blood glucose levels while continuing to lower postprandial blood glucose 
levels by controlling the release of nateglinide. Although the cause of this finding is 
currently unclear, the following possible reasons can be considered.   
1) Nateglinide and SU type blood glucose regulator bind to SU receptors on 
pancreas  cells.  As a result, Ca2+ channels open and extracellular Ca2+ 
flows into the  cells resulting in secretion of insulin3). 
2) In the case of SU type compounds, although basal insulin secretion is 
maintained since there is comparatively strong affinity for SU receptors, 
first-phase insulin secretion due to Ca2+ influx does not occur3).   
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3) On the other hand, in the case of a quick action/short duration blood glucose 
regulator like nateglinide, since the drug rapidly dissociates from the SU 
receptors3), there is a correlation between plasma drug concentration and 
blood glucose levels, which is thought to enable decreases in both PBG and 
FBG.  Furthermore, further studies will be required in the future to assess the 
blood glucose lowering effects during continuous administration of a 
nateglinide controlled release formulation so as to lower postprandial blood 
glucose and fasting blood glucose levels.   
A correlation was observed between plasma nateglinide concentrations and blood 
glucose levels.  However, there were no well-defined correlations observed between 
plasma insulin concentrations and blood glucose levels similar as to when only enteric 
coated granules were administered.  This is believed to be due to having sampled 
blood from a vein in the leg. Kawamori et al. and other researchers have pointed out 
that plasma insulin concentrations of peripheral veins do not serve as an indicator of 
insulin secretion from the pancreas based on the results of insulin kinetics and 
metabolism studies using normal fasting dogs32-34). In addition, venous plasma insulin 
concentrations after having passed through the liver have been indicated as being 50% 
or less of concentrations in the portal vein35, 36). In other words, the control of blood 
glucose levels is thought to take place based on insulin concentration in the portal vein 
and not in the peripheral blood. It is thought that a correlation between plasma insulin 
concentrations and blood glucose levels would be observed if it were possible to 
measure plasma insulin concentration in the portal vein.   
On the basis of these results, it is confirmed to decrease both PBG and FBG in 
normal beagle dogs with controlled release of nateglinide. Nateglinide controlled 
- 52 - 
release formulation is considered to enable control of both PBG and FBG for moderate 
and severe diabetes patients. 
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Chapter 3 
Research for Dosage Form of Nateglinide Controlled Release 
Formulation 
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3.1. Design of Nateglinide Controlled Release Formulation Containing  
Immediate Release Granules and Enteric Coated Granules, and  
Evaluation of Dissolution Profile 
 
Summary 
The author designed a single unit type controlled release tablet containing 
nateglinide to decrease both PBG and FBG in normal beagle dogs. The tablet contains 
60 mg of nateglinide in an immediate release portion, and 90 mg of nateglinide in a 
controlled release portion. Compressionable enteric coated granules were selected as 
the controlled release portion to primarily decrease FBG, and they were prepared by an 
aqueous coating with Eudragit®. Three types of nateglinide controlled release tablets 
were obtained, and their weights were 418.1 – 425.1 mg/tablet containing the above 
compressionable enteric coated granules. Even after tableting, the dissolution behavior 
of enteric coated granules was maintained approximately. From the view point of 
dissolution behavior, it was expected that it was able to control both PBG and FBG. 
 
Materials and Methods 
Nateglinide (Ajinomoto Co. Inc., Japan),  lactose mono-hydrate (DMV, Japan), 
hydroxypropylcellulose (Nihon Soda, Japan), low-substituted hydroxypropyl cellulose 
(Shin-etsu Chemical Co. Ltd., Japan), magnesium stearate (Mg-St, 
Taiheikagakusangyo, Japan), methacrylic acid copolymer LD (Eudragit®L30D-55, 
Röhm GmbH, Germany), poly (methyl acrylate-co-methyl methacrylate- co- 
methacrylic acid) (Eudragit® FS30D, Röhm GmbH, Germany), ethylacrylate 
methylmethacrylate copolymer dispersion (Eudragit® NE30D, Röhm GmbH, 
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Germany), croscarmellose sodium (Ac-Di-Sol®, Asahikasei Co. Ltd., Japan), triethyl 
citrate (CBC, Japan), polysorbate 80 (Wako Pure Chemical Co. Ltd., Japan),  glycelyl 
monostearate (Higuchi Shoukai, Co. Ltd., Japan), sodium hydroxide (JIS K8576, 
reagent grade, Junseikagaku, Japan), citric acid (JIS K8283, reagent grade, 
Junseikagaku, Japan) were used in the study.  
A high shear mixer (FS-10JD, Fukae Powtec, Japan), an extrusion granulator 
(DG-L1, Fuji Paudal, Japan), a cutter mill (New Speed Mill (ND-10), Okadaseiko, 
Japan), a spherized granulator (Q-230, Fuji Paudal, Japan), a fluidized bed 
granulator/dryer (FLO-1, Freund Industry Co., Japan), a V-blender (VFS, 
Tsutsuirikakagaku, Japan), a tableting machine (HT-AP15SSII, Hata Machinery, 
Japan),  and a microfluidizer (Nanomizer Inc., Japan) were used. 
Three-hundred-seventy-five grams of nateglinide, 637.5 g of lactose monohydrate 
and 450.0 g of low-substituted hydroxypropyl cellulose were mixed in a high shear 
mixer for 10 min.  Subsequently, 1,035 g of a binding solution of 15 g of 
hydroxypropyl cellulose in water was added, and granulation was conducted for 2.5 
min (agitator: 400 rpm, chopper: 3600 rpm).  The total amount of the resulting 
product was uniformly granulated with a cutter mill (2000 rpm, screen: 1×10 mm), and 
dried with a fluidized bed drier (FLO-1) (inlet air temperature: 80oC).  The obtained 
granules were screened through a sieve of 850 m.  The granular product remaining 
on the sieve of 850 m was forcibly passed through the sieve, and both products were 
mixed to form immediate release granules. 
Composition of core granules is shown in Table 3-1. Five-hundred grams of 
nateglinide, 5 g of hydroxypropylcellulose, and 10 g of polysorbate 80 were suspended 
and dissolved in 800 g of water with a microfluidizer (pressure: 1200 kgf/cm2). After 
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mixing this suspension with the mixture of 22.1 g of lactose monohydrate and 252.8 g 
of croscarmellose sodium, extrusion granulation was conducted (diameter: 1.0 mmφ). 
The resulting granules were rounded by a spherical granulator (rotor agitation: 450 
rpm), and then dried in a fluidized bed dryer (inlet temperature: 80oC). Fractions of 
850 μm - 1400 μm granules were obtained by grading, and then they were used for 
coating. Table 3-2 shows the compositions of the used enteric coating suspensions. The 
resulting core granules were coated with the coating solutions using a fluidized bed 
coating machine (outlet temperature during coating : 26 – 31oC (Enteric Coated 
Granules (a)), 18 - 26oC (Enteric Coated Granules (b)), 20 – 26oC (Enteric Coated 
Granules (c)). After drying, these enteric coated granules were annealed at 35oC 
overnight. Particle diameter was evaluated by sieving method. Loss on drying test was 
conducted at 80oC with an infrared moisture determination balance (AD-230, KETT 
ELECTRIC LABORATORY, Japan).  
 
 
Table 3-1: Composition of core granules for enteric coating. 
 
 
 
 
*: The composition when nateglinide is 90 mg. 
  
nateglinide 90.0
lactose monohydrate 4.0
croscarmellose sodium 45.5
hydroxypropylcellulose 0.9
polysorbate 80 1.8
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Table 3-2: Composition of enteric coating suspension.  
 
 
 
 
 
 
 
The obtained enteric coated granules and immediate release granules were mixed 
with a V-blender (38 rpm, 10 min). Then the obtained granules and magnesium stearate 
were mixed (38 rpm, 5 min).  The granular product was tableted to obtain the 
nateglinide controlled release tablets (target hardness: ca. 30 N). Hardness of the 
obtained tablets was evaluated with tablet tester (TS-50N, Okada Seiko, Japan). 
The dissolution behaviors of nateglinide preparations were evaluated (JP15, paddle 
method, 50 rpm, test fluid: 900 mL, nateglinide:  90 or 150 mg/vessel) with a 
dissolution tester（NTR-VS6P, Toyama Sangyo Co. Ltd., Japan). Each test fluid was 
JP1 fluid (JP15, Dissolution Test Fluid No.1) containing 0.6 w/v% (nateglinide: 90 
mg/vessel), 1.2 w/v% (nateglinide: 150 mg/vessel) of polysorbate 80 for pH=1.2, and 
Clark-Lubs buffer for pH=5.5-6.8. Dissolution rates were determined with a reversed 
phase HPLC system consisting of an L-6000 constant flow pump and an L-4000 UV 
detector operating at 210 nm (Hitachi Corp., Japan). Separations were performed with 
a reversed phase C-18 column (4.5×150 mm, GL Science, Japan). The mobile phase 
consisted of acetonitrile – pH=2.5 phosphate buffer (55:45 v/v).  Nateglinide eluted at 
weight [g] solid content [g] weight [g] solid content [g] weight [g] solid content [g]
methacrylic acid copolymer LD 208.0 62.40 70.0 21.00
poly(methyl acrylate-co-methyl
methacrylate- co- methacrylic acid) 630.0 189.00 700.0 210.00
2 w/w% NaOH aq. 3.5 0.07
ethylacrylate methylmethacrylate
copolymer dispersion 104.0 31.20
20 w/w% citric acid aq. 1.0 0.20
Glycelyl monostearate 2.9 2.90 6.3 6.30 6.3 6.30
Polysorbate 80 1.1 1.10 1.1 1.10
33 w/w% Polysorbate 80 aq. 1.5 0.50
Triethyl citrate 9.8 9.80 10.3 10.30 10.5 10.50
water 624.0 1812.3 1400.0
total 954.7 107.07 2530.0 227.70 2117.9 227.90
（a） （c）（b）
Enteric Coated Granules
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about 10 min at 40oC (at a flow rate of 1.5 mL/min). 
 
Results 
In order to decrease FBG with nateglinide, it is necessary to conduct a sustained 
release of nateglinide. When administering enteric coated granules with meal, it was 
reported that a sustained release of the drug was achieved. Moreover, it was reported 
that nateglinide was only partially absorbed in the stomach, but was well absorbed in 
the whole area of the intestines, according to the in situ experiment in rats using a 
ligated loop method37). As in the above mentioned results, focusing the enteric coated 
granule, the author aimed to design compressionable enteric coated granules as a 
controlled release portion to primarily decrease FBG, and a single unit type nateglinide 
controlled release tablet containing the enteric coated granules. 
Nateglinide core granules were coated using the coating suspensions shown in Table 
3-2 to prepare 3 types of compressionable enteric coated granules. The formulations 
were designed as shown in Reference 26. It was thought to be necessary to coat 15 
w/w% or more of enteric coating material on core granules to obtain acid resistance  
(see 2.1.).  Therefore, 15 w/w% or more of enteric coating materials were coated on 
the core granules (Enteric Coated Granules (a): 22 w/w% of methacrylic acid 
copolymer LD (Eudragit®L30D-55), Enteric Coated Granules (b): 31.4 w/w% of 
methacrylic acid copolymer LD + poly (methyl acrylate-co-methyl methacrylate- co- 
methacrylic acid) (Eudragit®FS30D) (1:9 dry substance weight ratio), Enteric Coated 
Granules (c): 31.6 w/w% of poly (methyl acrylate-co-methyl methacrylate- co- 
methacrylic acid)). The loss on drying values were 3.6 w/w% (Enteric Coated Granules 
(a)), 3.4 w/w% (Enteric Coated Granules (b)), 3.2 w/w% (Enteric Coated Granules (c)) 
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respectively. The average diameter of the obtained compressionable enteric coated 
granules was about 1 mm.  
Three types of nateglinide controlled release tablets were prepared with the 
composition shown in Table 3-3 (Tablet A, B, C, concave shape, diameter: 10 mmφ). 
The amounts of nateglinide in both an immediate release portion and a controlled 
release portion were decided according to Chapter 2 (the immediate release portion: 60 
mg of nateglinide, the controlled release portion: 90 mg of nateglinide). The average 
diameter of used immediate release granules was about 250 μm.  
  
Table 3-3: Composition of nateglinide controlled release tablet containing 
compressionable enteric coated granules. 
 
 
 
 
 
 
The acid resistance of the compressionable enteric coated granules was evaluated in 
JP1 fluid (Table 3-4). The dissolution rates at 120 min in JP1 fluid of Enteric Coated 
Granules (a), (b) and (c) were 6.4%, 0.4%, 0.4% respectively, demonstrating sufficient 
acid resistance. Then, the dissolution behavior in neutral pH region was also evaluated 
(Figure 3-1). In this study, dissolution pH is defined as the pH at which the 60 min 
dissolution rate reaches 10% or more. Enteric Coated Granules (a), (b) and (c) were 
confirmed to have a different dissolution pH, demonstrating values of 6.0, 6.5 and 6.8, 
Tablet A 226.4 （a） 192.3 6.4 425.1
Tablet B 226.4 （b） 187.5 4.2 418.1
Tablet C 226.4 （c） 187.9 4.2 418.5
total weight
[mg]
natglinide
controlled
release tablet
immediate release
granules
(nateglinide: 60 mg)
[mg]
Mg-St
[mg]
Enteric Coated Granules
(nateglinide: 90 mg)
[mg]
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respectively. The dissolution rate of nateglinide became slower in the order of Enteric 
Coated Granules (a), (b) and finally (c). The dissolution rate of nateglinide from 
immediate release tablet (Fastic® tablet) or of immediate release granules is nearly 
100% in both an acid and neutral pH.  
In JP1 fluid, dissolution rates at 120 min of the obtained Tablets A, B and C were 
around 40%. Dissolution behaviors were also evaluated for the obtained Tablet A, B 
and C (Table 3-5, Figure 3-2).  
 
Table 3-4: Dissolution rate at 120 min of compressionable enteric coated granules in 
JP1 fluid*. 
 
 
 
nateglinide: 90 mg/vessel, n=3, mean ± SD.  
*: JP1 fluid containing 0.6 w/w% polysorbate 80. 
 
Table 3-5: Dissolution rate at 120 min of nateglinide controlled release tablets in JP1 
fluid*. 
 
 
 
 
nateglinide: 150 mg/vessel, n=3, mean ± SD. 
              *: JP1 fluid containing 1.2 w/w% polysorbate 80. 
%dissolved in JP1fluid*
at 120 min [%]
Enteric Coated Granules （a） 6.4 ± 0.0
Enteric Coated Granules （b） 0.4 ± 0.0
Enteric Coated Granules （c） 0.4 ± 0.2
%dissolved in JP1fluid*
at 120 min [%]
Tablet A 43.3 ± 1.3
Tablet B 40.0 ± 1.8
Tablet C 37.3 ± 1.5
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Figure 3-1: pH Relationship of dissolution rate at 60 min of enteric coated granules.   
JP15 paddle method (50 rpm), nateglinide: 90 mg/vessel, n=3, mean ± SD, 
        medium : Clark-Lubs buffer (KH2PO4 + NaOH). 
○：Enteric Coated Granules (a). 
ᇞ：Enteric Coated Granules (b). 
□：Enteric Coated Granules (c). 
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Figure 3-2: pH Relationship of dissolution rate at 60 min of nateglinide controlled 
release tablets.   
JP15 paddle method (50 rpm), nateglinide: 150 mg/vessel, n=3, mean ± 
SD, medium: Clark-Lubs buffer (KH2PO4 + NaOH). 
●：Tablet A. 
▲：Tablet B. 
■：Tablet C. 
immediate release portion : 60 mg of nateglinide.  
controlled release portion : 90 mg of nateglinide. 
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Discussion 
Enteric Coated Granules (a), (b) and (c) were confirmed to have acid resistance and 
to have a different dissolution pH, demonstrating values of 6.0, 6.5 and 6.8, 
respectively. The dissolution rate of nateglinide became slower in the order of Enteric 
Coated Granules (a), (b) and finally (c). Furthermore it was possible to control the 
dissolution pH value of enteric coated granules by mixing more than 2 kinds of enteric 
coating materials. The dissolution rate of nateglinide from immediate release tablet 
(Fastic® tablet) or of immediate release granules is nearly 100% in both an acid and 
neutral pH. It is suggested that these compressionable enteric coated granules 
effectively lowered FBG with hardly any decrease in PBG according to previous study. 
A nateglinide controlled release tablet was designed, comprised of both immediate 
release granules and compressionable enteric coated granules. The tablet contained 60 
mg of nateglinide in the immediate release portion and 90 mg of nateglinide in the 
controlled release portion. Three types of nateglinide controlled release tablets were 
obtained, and their weights were 418.1 – 425.1 mg/tablet. The hardness values of the 
obtained tablets were about 30 N. These values are lower than those of conventional 
film coated tablets in the market, but are similar to those of orally disintegrated 
tablets38). Further process studies are required to make the above tablets commercially 
produced for the market. 
Dissolution behaviors were also evaluated for the obtained Tablet A, B and C (Table 
3-5, Figure 3-2). In JP1 fluid, dissolution rates at 120 min of the obtained Tablets A, B 
and C were around 40%. This means that only nateglinide contained in the immediate 
release portion was dissolved under this dissolution testing condition (60 mg/150 mg = 
40 %), and that acid resistance of enteric coated granules was maintained even after 
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tableting26). In neutral pH (pH = 5.5 - 6.8), although the little change in pH relationship 
of dissolution rate was observed when compared with those shown in Figure 3-1, the 
dissolution behavior of enteric coated granules was maintained approximately even 
after tableting. It is thought that further process control studies are required for enteric 
coating process and tableting process in order to precisely control the dissolution 
behavior. The content uniformity of both immediate release granules and enteric coated 
granules in the obtained tablets was not evaluated. However, it was thought that both 
immediate release granules and enteric coated granules were mixed uniformly 
according to the deviations of dissolution rates (Table 3-5).  
As the above results, it was expected that it was able to control both PBG and FBG 
using this nateglinide controlled release tablet in beagle dogs. 
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3.2. Design of Nateglinide Controlled Release Formulation Containing 
Immediate Release Granules and Erosion Matrix Tablet, and 
Evaluation of Dissolution Profile 
 
Summary 
The author designed a single unit type tablet formulation containing nateglinide to 
decrease both PBG and FBG in normal beagle dogs. The tablet comprises both a core 
tablet (an erosion matrix tablet: a controlled release portion (nateglinide: 90 mg)) and 
an outer shell (an immediate release portion (nateglinide: 60 mg)). The weight, the 
diameter and the hardness of the obtained tablet were 416.1 mg, 10 mmφ, about 60 N, 
respectively.  
The dissolution study of the obtained tablet in pH 1.2 or 6.8 showed that the 
nateglinide in the immediate release portion dissolved in almost 30 min, and that 30 
min after the dissolution test started, the nateglinide in the controlled release portion 
had dissolved slowly. As the above results, it was expected that it was able to decrease 
both PBG and FBG using this nateglinide controlled release tablets in beagle dogs. 
 
Materials and Methods 
Nateglinide (Ajinomoto Co. Inc., Japan), hydroxypropylcellulose (Nihon Soda, 
Japan), lactose mono-hydrate (DMV Japan), hydroxypropylmethylcellulose2910 
(HPMC2910), hydroxypropylmethylcellulose2208 (HPMC2208), low-substituted 
hydroxypropylcellulose (Shin-etsu Chemical Co. Ltd., Japan), microcrystalline 
cellulose (Asahikasei, Japan), macrogol 6000 (Nihon Oil and Fats Co. Ltd., Japan), 
magnesium stearate (Mg-St, Taiheikagakusangyo, Japan), were used in the study.  
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A high shear mixer (MINI/FS-10JD, Fukae Powtec, Japan), a fluidized bed 
granulator (FLO-1, Freund Industry Co., Japan), a rotating cutter type mill (New speed 
mill, Okadaseiko, Japan), a tableting machine (HT-AP, Hata Machinery, Japan), and a 
pan type coating machine (Freund Industry Co., Japan) were used. Hardness of the 
obtained tablets was evaluated with a tablet tester (TS-50N, Okada Seiko, Japan). 
Three-hundred-and-seventy-five grams of nateglinide, 637.5 g of lactose 
monohydrate and 450.0 g of hydroxypropylcellulose having a low degree of 
substitution were mixed with a high shear mixer （ FS-10JD ）  for 10 min.  
Subsequently, 1,035 g of a binding solution of 15 g of hydroxypropylcellulose in water 
was added, and granulation was conducted for 2.5 min. The total amount of the 
resulting granular product was uniformly granulated with a new speed mill, and dried 
with a fluidized bed drier.  The obtained granules were screened through a sieve of 
850 m.  The granular product remaining on the sieve of 850 m was forcibly passed 
through the sieve, and both products were mixed to form immediate release granules. 
The compositions are shown in Table 3-6. In the case of Erosion Matrix Tablet A, 
nateglinide and hydroxypropylmethylcellulose were charged in a high shear mixer 
(MINI), and mixed. In the case of Erosion Matrix Tablets B and C, nateglinide, 
hydroxypropylmethylcellulose and microcrystalline cellulose were charged in a high 
shear mixer (MINI), and mixed. Then, water was added, and granulation was 
conducted for 1.5 min.  The resulting granular product was dried on a shelf, and 
screened using a sieve with an opening of 850 m. The thus-obtained granular product 
was mixed with magnesium stearate, and the mixture was tabletted to obtain erosion 
matrix tablets using a 7.5 mmφ punch. In the case of Erosion Matrix Tablet C, the 
resulting erosion matrix tablets were coated using a coating solution formed by 
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dissolving 50.0 g of hydroxypropylmethyl cellulose 2910 (HPMC2910) and 10.0 g of 
macrogol 6000 in 1,440 g of water (12.5% of hydroxypropylmethyl cellulose based on 
the weight of the erosion matrix tablet was coated). 
 
Table 3-6: Composition of erosion matrix tablets.  
 
 
 
 
 
 
Nateglinide controlled release tablets containing an erosion matrix tablet were 
prepared using the HPMC2910 coated erosion matrix tablets (Erosion Matrix Tablet C) 
and the immediate release granules (Figure 3-3, Table 3-7, tablet diameter: 10 mmφ).  
  
A B C
nateglinide 90.0 90.0 90.0
hydroxypropylmethylcellulose 2910 45.1 22.5
hydroxypropylmethylcellulose 2208 22.5
microcrystalline cellulose 37.5 37.5
magnesium stearate 2.8 2.3 3.0
hydroxypropylmethylcellulose 2910 19.2
macrogol 6000 3.9
137.8 152.3 176.1total [mg]
ingredients
Erosion Matrix Tablet
core tablet
coating film
- 68 - 
      
Figure 3-3: The section of nateglinide controlled release tablet containing both 
immediate release granules and an erosion matrix tablet. 
          Immediate release granules form an outer shell. Core tablet is 
HPMC2910-coated erosion matrix tablet. 
 
Table 3-7: Composition of the tablet containing Erosion Matrix Tablet C [mg]. 
 
 
 
 
 
The dissolution profiles of nateglinide preparations were evaluated (JP15, paddle 
method, 50 rpm, test fluid: 900 mL, nateglinide: 90 or 150 mg/vessel) with a 
dissolution tester (NTR-VS6P, Toyama Sangyo Co. Ltd., Japan). Each test fluid was 
JP1 fluid (JP15, Dissolution Test Fluid No.1) containing 0.6 w/v% (nateglinide: 90 
mg/vessel), 1.2 w/v% (nateglinide: 150 mg/vessel) polysorbate 80 for pH=1.2, and 
Clark-Lubs buffer for pH=6.8 (JP2 fluid: JP15, Disintegration Test Fluid No.2).  
core tablet
HPMC2910 coated erosion matrix tablet
outer shell
immediate release granules
part component weight [mg]
core tablet Erosion Matrix Tablet C 176.1
immediate release granules 236.4
Magnesium stearate 3.6
416.1total
outer shell
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  Dissolution rates were determined with a reversed phase HPLC system consisting 
of an L-6000 constant flow pump and an L-4000 UV detector operating at 210 nm 
(Hitachi Corp., Japan). Separations were performed with a reversed phase C-18 
column (4.5×150 mm, GL Science, Japan). The mobile phase consisted of an 
acetonitrile – pH=2.5 phosphate buffer (55:45 v/v).  Nateglinide eluted in about 10 
min at 40oC (at a flow rate of 1.5 mL/min). 
 
Results 
Three types of nateglinide erosion matrix tablets as controlled release portions were 
prepared according to Table 3-6 (Erosion Matrix Tablet A, B, C).  The amount of 
nateglinide in one erosion matrix tablet was determined to be 90 mg according to the 
results of Chapter 2. Tablet hardness values of the Erosion Matrix Tablet A and B were 
about 50 N. The value of the Erosion Matrix Tablet C was about 300 N, due to coating 
with HPMC2910. 
Dissolution profile of the obtained erosion matrix tablets was evaluated in JP1 fluid 
containing 0.6 w/v% Polysorbate 80 or JP2 fluid. Nateglinide is a poorly water-soluble 
drug. Polysorbate 80 was added to acid pH testing fluid to satisfy the sink condition. 
The results are shown in Figure 3-4 and 3-5.  
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Figure 3-4: Dissolution profile of nateglinide erosion matrix tablets in JP1 fluid 
containing 0.6w/v% polysorbate 80. 
 nateglinide: 90 mg/vessel, mean ± SD, n=3. 
           ○：Erosion Matrix Tablet A. 
       ᇞ：Erosion Matrix Tablet B. 
       □：Erosion Matrix Tablet C. 
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Figure 3-5: Dissolution profile of nateglinide erosion matrix tablets in JP2 fluid.  
         nateglinide: 90 mg/vessel , mean ± SD, n=3. 
        ○：Erosion Matrix Tablet A. 
        ᇞ：Erosion Matrix Tablet B. 
        □：Erosion Matrix Tablet C. 
 
The dissolution rate at pH 1.2 decreased in the order of nateglinide Erosion Matrix 
Tablet A, B and finally C. The dissolution rate at pH 6.8 also decreased in the order of 
nateglinide Erosion Matrix Tablet A, B and finally C. In the case of Tablet C, the lag 
time of dissolution was observed. It was assumed to be due to the HPMC2910 coating.  
  The dissolution rate of nateglinide immediate release tablets (Fastic® tablets) under 
the same conditions is nearly 100% within 30 min. 
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After deciding to focus on Erosion Matrix Tablet C (HPMC2910 coated erosion 
matrix tablet), which was expected to effectively lower FBG with hardly any decrease 
in PBG, a nateglinide controlled release tablet was designed with both Erosion Matrix 
Tablet C (90 mg of nateglinide) and immediate release granules (60 mg of nateglinide). 
The amount of nateglinide in the immediate release portion and in the controlled 
release portion was determined according to the results of Chapter 2. The diameter of 
the obtained tablet was 10 mm, and the hardness values of the tablets were about 60 N 
originating in the outer shell of the tablet. 
Dissolution profiles of the obtained nateglinide controlled release tablets containing 
Erosion Matrix Tablet C were evaluated in JP1 fluid containing 1.2 w/v% Polysorbate 
80 or JP2 fluid. The results are shown in Figure 3-6. About 35% of the total dose was 
dissolved in 30 min at both pH 1.2 and 6.8. This indicated that most of the nateglinide 
contained in the immediate release portion was dissolved in 30 min. The dissolution 
rate of nateglinide immediate release tablets (Fastic® tablets) under the same 
conditions is nearly 100% within 30 min. Thirty minutes after the test started, 
nateglinide was dissolved slowly at both pH1.2 and 6.8. These behaviors were the 
same as those of Erosion Matrix Tablet C.  
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Figure 3-6: Dissolution profile of the obtained nateglinide controlled release tablets 
containing an erosion matrix tablet. 
JP15 paddle method (50 rpm), n=3, nateglinide: 150 mg/vessel, mean ± SD, 
      medium: JP1 fluid containing 1.2 w/v% polysorbate 80 (○), JP2 fluid (□). 
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Discussion 
A single unit type tablet formulation containing nateglinide was designed to 
decrease both PBG and FBG in normal beagle dogs, using an erosion matrix tablet as a 
controlled release portion. The tablet comprised both a core tablet (an erosion matrix 
tablet: a controlled release portion) and an outer shell (an immediate release portion), 
and contained 60 mg of nateglinide in the immediate release portion and 90 mg of 
nateglinide in the controlled release portion. The weight, the diameter and the hardness 
of the obtained tablet were 416.1 mg, 10 mmφ and about 60 N, respectively. The tablet 
hardness values are similar to those of conventional film coated tablets in the market.  
In a dissolution study of the obtained tablet in pH1.2 or 6.8, nateglinide in the 
immediate release portion was almost dissolved in 30 min. Thirty minutes after the test 
starts, nateglinide in the controlled release portion was dissolved slowly. It was 
expected that it was able to control both PBG and FBG using this nateglinide 
controlled release tablets in beagle dogs.  
 Although further process studies are required to make the above tablets commercially 
produced for the market, from the view point of manufacturing robustness, the tablet 
containing an erosion matrix tablet is thought preferable to that containing enteric 
coated granules. 
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Chapter 4  
Multiple Administration Study with Nateglinide Controlled 
Release Formulation 
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4.1. Single Administration Study with Nateglinide Controlled Release 
Formulation Containing Immediate Release Granules and 
Erosion Matrix Tablet, and Evaluation of Nateglinide Plasma 
Concentration Profile 
 
Summary 
The author designed a single unit type tablet that comprised both a core tablet (an 
erosion matrix tablet: a controlled release portion (nateglinide: 90 mg)) and an outer 
shell (an immediate release portion (nateglinide: 60 mg)). The weight was 416.1 
mg/tablet. An in vivo single oral administration study with this tablet in normal beagle 
dogs showed the bioavailability value of the obtained nateglinide controlled release 
tablets containing erosion matrix tablet against nateglinide immediate release tablets 
was 73.6%, although the value of a nateglinide controlled release tablets containing 
enteric coated granules was 57.2-60.8%. From the view point of nateglinide plasma 
concentration profiles, it is expected to decrease both PBG and FBG. 
   
Materials and Methods 
  Nateglinide controlled release tablets (immediate release portion: 60 mg of 
nateglinide, controlled release portion: 90 mg of nateglinide), obtained in Chapter 3 
were used. 
Prior to being conducted, protocols of in vivo studies were assessed according to the 
guidelines of Ethical Committee in INA Research Co., Ltd. (Japan). The guideline was 
established based on "Doubutsu no aigo oyobi kanri ni kannsuru houritsu (Law about 
protection of an animal and management)" (October 1st, 1973, No. 105), 
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"Jikkendoubutsu no shiyou oyobi hokan nado ni kansuru kijyun (The standard about 
the breeding of an experimental animal and the safekeeping, etc.)" (March 1st, Sourihu 
No.6), “Jikkendoubutsu gaidorain no sakutei ni tsuite (About decision of an animal 
experiment guideline)" (November 5th, 1980, Sougakusho No.1513), "Daigaku nado ni 
okeru doubutsujikken ni tsuite (About the animal experiment that is conducted in a 
university" (May 25th, 1987, Bungakujyou No.141). One tablet was administered to 
normal male beagle dogs (body weight: ca. 10 kg) just before feeding. 
One-hundred-and-fifty grams of dry DS meal suspended in 600 g of hot water was 
forcibly administered to the beagle dogs with a syringe. Feeding was conducted within 
12 min. Blood samples were taken before and at 15, 30, 45, 60, 120, 240, 360, 540, 
720 and 1440 min (n=3). Determination of plasma nateglinide concentration is 
described in reference 31. 
 
Results 
Plasma nateglinide concentration profiles are shown in Figure 4-1. Results are also 
shown for nateglinide immediate release tablets only (nateglinide: 60 mg, 150 mg) 
used as controls. The nateglinide Cmax values were 13.10  3.05 μg/mL (Tmax: 0.75 hr) 
for nateglinide controlled release tablets, 15.63  1.08 μg/mL (Tmax: 0.75 hr) for the 
immediate release tablets (nateglinide: 60 mg), and 34.80  5.15 μg/mL (Tmax: 0.5 hr) 
for the immediate release tablets (nateglinide: 150 mg). There were no significant 
differences of the Cmax values observed between the immediate release tablets 
(nateglinide: 60 mg) and the nateglinide controlled release tablets (Student's t-test). 
This is because the Cmax values are based on the immediate release portion. This result 
confirms the above dissolution results. On the other hand, plasma nateglinide 
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concentrations from 4 hr to 12 hr after administration demonstrated an increasing trend 
due to the nateglinide erosion matrix tablet, and there was a significant difference of 
plasma nateglinide concentrations at 6 hr after administration between the immediate 
release tablets (nateglinide: 60 mg) and the nateglinide controlled release tablets 
(Student's t-test, p<0.05). The bioavailability value of the nateglinide controlled release 
tablets containing an erosion matrix tablet against nateglinide immediate release tablets 
was 73.6%, although the value was 57.2-60.8% in the case of the nateglinide 
controlled release tablet containing enteric coated granules (Chapter 3). 
 
 
 
 
 
 
 
 
 
Figure 4-1: Plasma nateglinide concentration profile after an oral administration of 
nateglinide preparations in fasted beagle dogs just before feeding.  
Each point and vertical bar represents mean ± SEM. 
： immediate release tablets (nateglinide: 60 mg), n=6. 
  ： immediate release tablets (nateglinide: 150 mg), n=6. 
○ ： nateglinide controlled release tablet containing an erosion matrix 
tablet, n=3. 
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Discussion 
A single unit type nateglinide controlled release tablet was designed to decrease both 
PBG and FBG. The tablet comprises both an erosion matrix tablet as a controlled 
release portion (nateglinide: 90 mg) and an immediate release granules as an 
immediate release portion (nateglinide: 60 mg). The weight, the diameter and the 
hardness of the obtained tablet were 416.1 mg, 10 mmφ and about 60 N, respectively.  
It was considered possible to decrease both PBG and FBG with this nateglinide 
controlled release tablet according to the plasma nateglinide concentration profiles. 
And it was possible to improve bioavailability, as compared with nateglinide controlled 
release tablet containing compressionable enteric coated granules. This means that the 
bioavailability value of the controlled release portion was improved by using an 
erosion matrix tablet. It is not obvious why the bioavailability value of administration 
of the tablet containing the erosion matrix tablet was higher than that of administration 
of the tablet containing enteric coated granules. Further study is necessary.  
It is assumed that not only the nateglinide controlled release tablets containing an 
erosion matrix tablet (immediate release portion: 60 mg of nateglinide, controlled 
release portion: 90 mg of nateglinide), but also the immediate release tablets 
(nateglinide: 150 mg) might decrease both PBG and FBG according to nateglinide 
plasma concentration profile. However, this nateglinide controlled release tablet is 
believed to be more useful than the immediate release tablets (nateglinide: 150 mg), 
because the ability to control both PBG and FBG without side effect, is easier. 
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4.2. Multiple Administration Study with Nateglinide Controlled 
Release Formulation Containing Immediate Release Granules 
and Erosion Matrix Tablet, and Evaluation of Nateglinide Plasma 
Concentration Profile, Blood Glucose Level and Change in 
Fasting Blood Glucose Level 
 
Summary 
An in vivo multiple oral administration study (b.i.d. (interval: 12 hr), 8 days) with 
nateglinide controlled release tablet in normal beagle dogs was conducted. That 
showed the reproducibility of nateglinide absorption, and decreases in both PBG and 
FBG even in the 8th days. The ability to decrease the blood glucose level did not 
weaken during a multiple administration. Furthermore, decrease in FBG at 9:00 A.M. 
was also observed. On the basis of the above results, nateglinide controlled release 
tablet was suggested to enable control of both PBG and FBG for moderate and severe 
diabetes patients. 
 
Materials and Methods 
  Nateglinide controlled release tablets containing an erosion matrix tablet (immediate 
release portion: 60 mg of nateglinide, controlled release portion: 90 mg of nateglinide),  
obtained in Chapter 3 were used. 
Prior to being conducted, protocols of in vivo studies were assessed according to the 
guidelines of Ethical Committee in INA Research Co., Ltd. (Japan). The guideline was 
established based on "Doubutsu no aigo oyobi kanri ni kannsuru houritsu (Law about 
protection of an animal and management)" (October 1st, 1973, No. 105), 
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"Jikkendoubutsu no shiyou oyobi hokan nado ni kansuru kijyun (The standard about 
the breeding of an experimental animal and the safekeeping, etc.)" (March 1st, Sourihu 
No.6), “Jikkendoubutsu gaidorain no sakutei ni tsuite (About decision of an animal 
experiment guideline)" (November 5th, 1980, Sougakusho No.1513), "Daigaku nado ni 
okeru doubutsujikken ni tsuite (About the animal experiment that is conducted in a 
university" (May 25th, 1987, Bungakujyou No.141). One tablet was administered to 
normal male beagle dogs (body weight: ca. 10 kg) just before feeding. 
One-hundred-and-fifty grams of dry DS meal suspended in 600 g of hot water was 
forcibly administered to the beagle dogs with a syringe. Feeding was conducted within 
12 min. An 8-day multiple administration study with the nateglinide controlled release 
tablets was conducted according to Table 4-1. Blood samples were taken at 9:00, 9:15, 
9:30, 9:45, 10:00, 11:00, 13:00, 15:00, 18:00, 21:00, 21:15, 21:30, 21:45, 22:00 and 
23:00 on the 1st day, 01:00, 05:00, 06:00 and 09:00 on the 2nd day, 09:00 on the 3rd, 4th, 
5th, 6th and 7th day, 9:00, 9:15, 9:30, 9:45, 10:00, 11:00, 13:00, 15:00, 18:00, 21:00, 
21:15, 21:30, 21:45, 22:00 and 23:00 on the 8th day, 01:00, 05:00, 06:00 and 09:00 on 
the 9th day after the 1st oral administration (n=3). Plasma nateglinide concentration was 
evaluated for samples of the 1st, 2nd, 8th and 9th day. Blood glucose level was evaluated 
for all blood samples.  
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Table 4-1 : Multiple administration study protocol. 
 
 
 
 
 
 
 
 
 
Blood was sampled from a leg vein. Whole blood was centrifuged at 1700 g for 15 
min at 5oC and plasma was collected for analysis. A 50 μL portion of internal standard 
solution was spiked into 0.5 mL plasma in an Eppendorf tube, followed by the addition 
of 0.5 mL of 0.05 mol/L pH=6.0 phosphate buffer. The mixture was vortex-mixed for 
10 s and applied to a Sep-Pak Vac tC18 cartridge that was pre-equilibrated with 5 mL 
of 0.05 mol/L pH=6.0 phosphate buffer. The cartridge was washed with 2 mL of water 
and finally eluted with 2 mL of ethanol. The elute was evaporated to dryness in vacuo 
at 30oC. The residue was dissolved in 0.2 mL of mobile phase and 20 μL of this 
solution was used for the HPLC sample. 
Plasma nateglinide concentration was determined31) with a two-column switching 
HPLC system consisting of a 600E multi solvent pump system, 515 HPLC pump 
(Waters, Japan), 2487 UV detector (Waters, Japan) operating at 210 nm, and  
SPV-N-6A column switching apparatus (GL Science, Japan). Separations were 
performed with an Inertsil ODS-3 reversed phase C-18 column (4.0×20 mm, GL 
The 1st day
The 2nd day
The 3rd day
The 4th day
The 5th day
The 6th day
The 7th day
The 8th day
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
09:00 21:00 00:00 03:00 06:0012:00 15:00 18:00
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
1 tablet/feeding
day night
△ △
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Science, Japan) and L-column ODS (4.6×250 mm, Kagakubushitsukenkyukikou, 
Japan). Three types of mobile phases were used consisting of acetonitrile: pH=6.6 0.05 
mol/L phosphate buffer = 3:7, v/v (Mobile Phase A), acetonitrile: pH=6.6 0.05 mol/L 
phosphate buffer = 45:55, v/v (Mobile Phase B), and acetonitrile: pH=6.6 0.05 mol/L 
phosphate buffer = 6:4, v/v (Mobile Phase C). The timetable of the column switching 
pattern is shown in Table 4-2. At a flow rate of 1.0 mL/min, nateglinide eluted in about 
7.5 min at 40oC. Blood glucose level was determined with the Fuji DRICHEM 3500S 
(FUJIFILM Co., Japan). 
 
Table 4-2: Column switching program. 
 
 
  
time[min.] 600E pump system 515 pump column switchinga)
0.0-0.7 Mobile Phase A Mobile Phase B 1
0.7-2.5 Mobile Phase A stop 2
2.5-8.0 Mobile Phase C Mobile Phase B 1
8.0-20.0 Mobile Phase A Mobile Phase B 1
a) 1: Mobile Phase A and C passed through a 600E pump system, injector and pre column.
       Mobile Phase B passed through a 515 pump, main column and detector.
    2: Mobile Phase A passed through a 600E pump system, injector, pre column, main column and detector.
       A 515 pump stopped.
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Results 
Plasma nateglinide concentration profiles during in vivo multiple oral administration 
(b.i.d. (interval: 12 hr), 8 days) of nateglinide controlled release tablet containing an 
erosion matrix tablet are shown in Figure 4-2. The nateglinide Cmax values were 12.65 
 0.92 μg/mL (Tmax: 2 hr (11:00, the 1st day)), 19.54  1.25 μg/mL (Tmax: 13 hr (22:00, 
the 1st day)), 16.12  2.84 μg/mL (Tmax: 2 hr (11:00, the 8th day)), and 16.63  1.72 
μg/mL (Tmax: 12.75 hr (21:45, the 8th day)).  There were no significant difference of 
the Cmax values observed among 13 hr (22:00, the 1st day) and 2 hr (11:00, the 8th day) 
and 12.75 hr (21:45, the 8th day) (Student's t-test). However, there were significant 
differences of the Cmax values observed between 2 hr (11:00, the 1st day) and 13 hr 
(22:00, the 1st day) (Student's t-test, P<0.05). Cmax values at 13 hr (22:00, the 1st day) 
and 2 hr (11:00, the 8th day) and 12.75 hr (21:45, the 8th day) demonstrated an 
increasing trend against that at 2 hr (11:00, the 1st day). This is because plasma 
nateglinide concentration just before administration was not zero (about 4 μg/mL, 
Figure 4-1) except at the first administration. It was found that nateglinide absorption 
during a multiple administration was reproducible. 
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Figure 4-2: Plasma nateglinide concentration profile during a multiple oral 
administration of nateglinide cotrolled release tablet containing an 
erosion matrix tablet in fasted beagle dogs just before feeding.  
Each point and vertical bar represent mean ± SEM. 
○: The 1st day, n=3. 
ᇞ: The 8th day, n=3. 
 
Blood glucose level profiles are shown in Figure 4-3.  Blood glucose level  
decreased to about 76.3% (1 hr, 10:00, the 1st day), 71.2% (6 hr, 15:00, the 1st day), 
75.1% (12.25 hr, 21:15, the 1st day), 83.3% (14 hr, 23:00, the 1st day), 81.4% (1 hr, 
10:00, the 8th day), 78% (6 hr, 15:00, the 8th day), 80.8% (12.25 hr, 21:15, the 8th day), 
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and 84.6% (14 hr, 23:00, the 8th day), as compared with blood glucose levels 
immediately before the 1st administration on the 1st day.   
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-3: Blood glucose level during a multiple oral administration of nateglinide 
controlled release tablet containing an erosion matrix tablet in fasted 
beagle dogs just before feeding.  
Each point and vertical bar represent mean ± SEM. 
: only feeding、n=6. 
○: 1st day, n=3. 
ᇞ: 8th day, n=3. 
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Change in FBG at 9:00 A.M. during a multiple oral administration of the nateglinide 
controlled release tablet was evaluated. The results are shown in Figure 4-4. FBG at 
9:00 decreased from the 1st day of administration to the 4th day by multiple 
administrations, and it rose after the 4th day. 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-4: FBG at 9:00 profile in multiple administration study. 
     n=3, mean ± SEM. 
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Discussion 
An in vivo multiple oral administration study (b.i.d. (interval: 12 hr), 8 days) with 
the nateglinide controlled release tablets using normal beagle dogs showed 
reproducibility of nateglinide absorption during this study. It was found that decreases 
in both PBG and FBG were observed. It was considered that the ability to decrease 
blood glucose level did not weaken during a multiple oral administration using the 
nateglinide controlled release tablet. Although it was initially believed that it would be 
difficult to continuously lower fasting blood glucose levels even if the release of an 
insulin secretion stimulator like nateglinide was able to be controlled, this study 
confirmed that the effect of decrease in both PBG and FBG did not weaken through a 
multiple oral administration, as shown in daytime of the 1st day with daytime of the 8th 
day.  
The level of decrease in blood glucose level in the daytime was larger than that at 
night time of the 1st day and the 8th day. Beagle dogs were in a fasting state at night 
time, because they were sleeping and not able to eat. It was considered difficult to 
lower blood glucose level at night time due to glucose production by the liver at night 
time39). Further study is necessary. Such as a study would use diabetic model dogs, and 
so forth.  
Change in FBG at 9:00 A.M. was evaluated. The reason the shape of the graph 
became convex below is unclear. FBG in the morning of the 4th day was about 73 
mg/dL. This blood glucose level is too low for normal beagle dogs. The reason the 
blood glucose level rose after the 4th day is thought to be due to homeostasis. If the 
effect on PBG and FBG is evaluated using the nateglinide controlled release tablets 
with diabetic model beagle dogs of which blood glucose level is high, the graph where 
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FBG decreases might be obtained by a multiple oral administration. 
As the above result, it is expected that a commercially available formulation will be 
designed, and that the effect on the blood glucose level of moderate and severe 
diabetes patients using nateglinide controlled release formulation will be evaluated in 
clinical trials. Furthermore, it is suggested that not only nateglinide but meglitinides 
(repaglinide, mitiglinide, etc.) can be used as an active ingredient in a controlled 
release tablet, because they are all classified as a short acting type insulin secretion 
stimulator40).  
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Chapter 5 
General Conclusions 
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With the controlled release form of insulin secretagogue, nateglinide, both PBG and 
FBG were able to be decreased in normal beagle dogs. A tablet that comprised of both 
immediate release granules and an erosion matrix tablet was considered preferable as a 
nateglinide controlled release formulation. In an 8 days-multiple administration study 
in normal beagle dogs, decrease in both PBG and FBG was observed even on 8th day, 
furthermore, decrease in FBG in the morning was also observed. Although there was 
concern that the effect of decrease in blood glucose level was weakened by multiple 
administration of an insulin secretagogue, weakening of the effect was not observed 
even when multiple-administering nateglinide controlled release formulation to normal 
beagle dogs. Nateglinide controlled release formulation is expected to control both 
PBG and FBG for moderate or severe type 2 diabetes.  
It is expected that a nateglinide controlled release formulation is useful for moderate 
or severe diabetes. However, it is only to be confirmed that both PBG and FBG are 
able to be decreased in an in vivo experiment according to the present results. For 
instance, only POP was confirmed. It is necessary to conduct a pre-clinical 
development and clinical development in order to submit a NDA in the future. 
The author describe below the counterplan for issues that will occur through 
pre-clinical development and clinical development. 
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Finally, a controlled release formulation containing a short-acting oral blood glucose 
regulator, not only nateglinide but meglitinides (repaglinide, mitiglinide, etc.) was 
suggested to enable control of both PBG and FBG for moderate and severe diabetes 
patients. With this controlled release formulation containing meglitinides, diabetics can 
have a future life without complications and with high a “Quality of Life”, which they 
have never experienced before.  
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